Condition Focus: Macrophage Polarization — The Flare Resolution Mechanism
Macrophages are the immune cells that determine whether an inflammatory response escalates or resolves. In their M1 (classically activated) state, they produce pro-inflammatory cytokines — TNF-α, IL-1β, IL-6 — that amplify inflammation and recruit more immune cells. In their M2 (alternatively activated) state, they produce anti-inflammatory mediators like IL-10 and release signals that promote tissue repair and debris clearance.
A gout flare is, at its core, a macrophage story. Resident macrophages in the joint encounter urate crystals, activate their M1 programme, and trigger the NLRP3 inflammasome cascade. The flare resolves when those same macrophages (or newly recruited ones) shift to the M2 phenotype and begin producing resolution signals. In chronic gout, this M1→M2 transition may be impaired — contributing to prolonged or recurrent flares.
This 2025 comprehensive review in Lasers in Medical Science confirms that PBM consistently promotes the M2 anti-inflammatory macrophage phenotype while suppressing M1 activation. The review synthesizes evidence from multiple wavelengths (red and NIR), energy densities, and inflammatory models to establish that macrophage polarization modulation is a reproducible, core mechanism of PBM’s anti-inflammatory effects.
This is not PBM masking pain or suppressing a single cytokine. It is PBM promoting the cellular programme that the body uses to resolve inflammation naturally — accelerating a process that in gout may be stalled or delayed.
G.O.A.T. for Gout Alignment:
The M1→M2 macrophage shift is arguably the most important mechanism through which the G.O.A.T. addresses gout. By promoting the resolution programme, PBM helps the body’s immune system complete the inflammatory cycle rather than stalling in the destructive M1 phase. The G.O.A.T.’s dual wavelengths support this shift through both surface (660 nm) and deep-tissue (850 nm) pathways.
Link to original research here
Editor’s note: The specific signalling pathways driving M1→M2 polarization are mapped in Tian et al 2023 (PI3K/AKT/mTOR) and PBM and Chondrocyte Catabolism 2025 (IL-6/JAK/STAT). Wavelength-specific effects on M1/M2 markers are demonstrated in Fernandes et al 2019. The Notch1-HIF-1α-NF-κB pathway in M1 suppression is RNA-seq confirmed in Ma et al 2022.
Related Articles
- PBM Increases M2 Macrophages via PI3K/AKT/mTOR at 980nm – Tian et al 2023
- PBM Mitigates Chondrocyte Catabolism via Macrophage M1 Polarization – 2025
- Wavelength and Timing in PBM-Induced Macrophage Polarization – Fernandes et al 2019
- PBM Modulates Macrophage via Notch1-HIF-1α-NF-κB: RNA-seq – Ma et al 2022
- Anti-Inflammatory Mechanisms of PBM – Hamblin 2017
Key Takeaways
- PBM consistently promotes anti-inflammatory M2 macrophage phenotype and suppresses pro-inflammatory M1
- M1→M2 shift IS the resolution mechanism for gout flares — PBM accelerates this transition
- Reproducible across multiple wavelengths, energy densities, and inflammatory models
- Not symptom masking — PBM promotes the body’s natural inflammation resolution programme
Study Overview
| Study Type: | Comprehensive review |
| Wavelength(s): | Red + NIR (multiple studies reviewed) |
| Treatment Protocol: | Varies across reviewed studies |
| Sample Size: | Comprehensive review of macrophage polarization studies |
| Primary Outcome: | M2 promotion, M1 suppression across inflammatory models |
Full Citation
Modulating macrophage polarization by photobiomodulation. (2025). Lasers in Medical Science, 40. View Publication
